Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price reached a new 52-week high on Tuesday . The stock traded as high as $51.82 and last traded at $49.54, with a volume of 129029 shares trading hands. The stock had previously closed at $51.74.
Gemini Therapeutics Stock Performance
The firm’s 50 day moving average price is $46.81 and its two-hundred day moving average price is $44.07. The firm has a market cap of $2.09 billion, a PE ratio of -48.50 and a beta of -0.12.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Recommended Stories
- Five stocks we like better than Gemini Therapeutics
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- 3 Leveraged ETFs to Multiply Returns
- What Are Trending Stocks? Trending Stocks Explained
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- What is the S&P/TSX Index?
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
